All data are based on the daily closing price as of October 28, 2026
h
Hanmi Pharm. Co.
128940.KO
276.06 USD
11.77
+4.45%
Overview
Last close
276.06 usd
Market cap
3.50B usd
52 week high
431.89 usd
52 week low
172.28 usd
Target price
489.01 usd
Valuation
P/E
20.4913
Forward P/E
N/A
Price/Sales
2.8322
Price/Book Value
3.1682
Enterprise Value
3.33B usd
EV/Revenue
2.6917
EV/EBITDA
11.1324
Key financials
Revenue TTM
1.24B usd
Gross Profit TTM
737.07M usd
EBITDA TTM
280.83M usd
Earnings per Share
12.78 usd
Dividend
1.49 usd
Total assets
1.51B usd
Net debt
128.62M usd
About
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.